MODERN POTENTIAL IN THE TREATMENT OF METABOLIC SYNDROME PATIENTS - FOCUS ON ENDOTHELIUM
Numerous publications on the use of p-blockers in patients with arterial hypertension (AH) and metabolic syndrome (MS) have reported adverse effects of these medications on carbohydrate and lipid metabolism, as well as reduced cerebral perfusion. This review presents the benefits of a third-generati...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2014-03-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/26 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849688789143781376 |
|---|---|
| author | V. B. Mychka S. N. Tolstov I. A. Salov Yu. V. Prokhorova E. I. Uzueva A. L. Vertkin |
| author_facet | V. B. Mychka S. N. Tolstov I. A. Salov Yu. V. Prokhorova E. I. Uzueva A. L. Vertkin |
| author_sort | V. B. Mychka |
| collection | DOAJ |
| description | Numerous publications on the use of p-blockers in patients with arterial hypertension (AH) and metabolic syndrome (MS) have reported adverse effects of these medications on carbohydrate and lipid metabolism, as well as reduced cerebral perfusion. This review presents the benefits of a third-generation p-blocker — nebivolol (Nebilet®) — in the treatment of MS patients. The authors refer to their own findings that demonstrate effectiveness and safety of nebivolol monotherapy in individuals with AH and MS. Nebivolol treatment resulted in a sustained reduction of systolic and diastolic blood pressure levels and also improved carbohydrate and lipid metabolism parameters, which beneficially differentiates nebivolol from all other known p-blockers. Nebivolol treatment did not demonstrate any negative effects on thyroid hormone levels and reduced aldosterone levels. Nebivolol-induced increase in the endothelial production of nitric oxide resulted in a significant improvement of cerebral perfusion. Moreover, nebivolol treatment a reduction in mean 24-hour QT interval duration, which was increased at baseline. These findings suggest a beneficial effect of nebivolol on myocardial electrophysiology. Nebivolol appears to be a promising medication in the treatment of patients with MS and AH. |
| format | Article |
| id | doaj-art-3f5551cd66c64615abdba9fe3df5a893 |
| institution | DOAJ |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2014-03-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-3f5551cd66c64615abdba9fe3df5a8932025-08-20T03:21:51Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202014-03-010310711310.15829/1560-4071-2014-3-107-11326MODERN POTENTIAL IN THE TREATMENT OF METABOLIC SYNDROME PATIENTS - FOCUS ON ENDOTHELIUMV. B. Mychka0S. N. Tolstov1I. A. Salov2Yu. V. Prokhorova3E. I. Uzueva4A. L. Vertkin5A.I. Evdokimov Moscow State Medico-Stomatological University, MoscowV.I. Razumovskyi Saratov State Medical University, Saratov, RussiaV.I. Razumovskyi Saratov State Medical University, Saratov, RussiaA.I. Evdokimov Moscow State Medico-Stomatological University, MoscowA.I. Evdokimov Moscow State Medico-Stomatological University, MoscowA.I. Evdokimov Moscow State Medico-Stomatological University, MoscowNumerous publications on the use of p-blockers in patients with arterial hypertension (AH) and metabolic syndrome (MS) have reported adverse effects of these medications on carbohydrate and lipid metabolism, as well as reduced cerebral perfusion. This review presents the benefits of a third-generation p-blocker — nebivolol (Nebilet®) — in the treatment of MS patients. The authors refer to their own findings that demonstrate effectiveness and safety of nebivolol monotherapy in individuals with AH and MS. Nebivolol treatment resulted in a sustained reduction of systolic and diastolic blood pressure levels and also improved carbohydrate and lipid metabolism parameters, which beneficially differentiates nebivolol from all other known p-blockers. Nebivolol treatment did not demonstrate any negative effects on thyroid hormone levels and reduced aldosterone levels. Nebivolol-induced increase in the endothelial production of nitric oxide resulted in a significant improvement of cerebral perfusion. Moreover, nebivolol treatment a reduction in mean 24-hour QT interval duration, which was increased at baseline. These findings suggest a beneficial effect of nebivolol on myocardial electrophysiology. Nebivolol appears to be a promising medication in the treatment of patients with MS and AH.https://russjcardiol.elpub.ru/jour/article/view/26metabolic syndromearterial hypertensionnitric oxidep-blockersnebivolol |
| spellingShingle | V. B. Mychka S. N. Tolstov I. A. Salov Yu. V. Prokhorova E. I. Uzueva A. L. Vertkin MODERN POTENTIAL IN THE TREATMENT OF METABOLIC SYNDROME PATIENTS - FOCUS ON ENDOTHELIUM Российский кардиологический журнал metabolic syndrome arterial hypertension nitric oxide p-blockers nebivolol |
| title | MODERN POTENTIAL IN THE TREATMENT OF METABOLIC SYNDROME PATIENTS - FOCUS ON ENDOTHELIUM |
| title_full | MODERN POTENTIAL IN THE TREATMENT OF METABOLIC SYNDROME PATIENTS - FOCUS ON ENDOTHELIUM |
| title_fullStr | MODERN POTENTIAL IN THE TREATMENT OF METABOLIC SYNDROME PATIENTS - FOCUS ON ENDOTHELIUM |
| title_full_unstemmed | MODERN POTENTIAL IN THE TREATMENT OF METABOLIC SYNDROME PATIENTS - FOCUS ON ENDOTHELIUM |
| title_short | MODERN POTENTIAL IN THE TREATMENT OF METABOLIC SYNDROME PATIENTS - FOCUS ON ENDOTHELIUM |
| title_sort | modern potential in the treatment of metabolic syndrome patients focus on endothelium |
| topic | metabolic syndrome arterial hypertension nitric oxide p-blockers nebivolol |
| url | https://russjcardiol.elpub.ru/jour/article/view/26 |
| work_keys_str_mv | AT vbmychka modernpotentialinthetreatmentofmetabolicsyndromepatientsfocusonendothelium AT sntolstov modernpotentialinthetreatmentofmetabolicsyndromepatientsfocusonendothelium AT iasalov modernpotentialinthetreatmentofmetabolicsyndromepatientsfocusonendothelium AT yuvprokhorova modernpotentialinthetreatmentofmetabolicsyndromepatientsfocusonendothelium AT eiuzueva modernpotentialinthetreatmentofmetabolicsyndromepatientsfocusonendothelium AT alvertkin modernpotentialinthetreatmentofmetabolicsyndromepatientsfocusonendothelium |